TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20023246

Group type: EXPERIMENTAL
Intervention: Autologous three-cellular cultured skin substitutes (CSS)
Number of subjects: 11
Study: 20026770

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6705
Study: 20026777

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study: 20027045

Group type: EXPERIMENTAL
Intervention: High concentrations of Atopobium vaginae (10^6/mL or more)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High concentrations of Gardnerella vaginalis (10^7/mL or more)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High concentrations of A vaginae and G vaginalis together
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High vaginal fluid concentrations of A vaginae and G vaginalis
Number of subjects: 90
Study: 20028332

Group type: COMPARATOR
Intervention: Tat vaccine administered 5 times, every four weeks, subcutaneously (SC) with alum adjuvant or intradermically (ID) without adjuvant at doses of 7.5 microg, 15 microg, or 30 microg.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tat vaccine (therapeutic immunization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tat vaccine
Number of subjects: 0
Study: 20028530

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 111
Study: 20031382

Group type: EXPERIMENTAL
Intervention: Montelukast 10mg added to ICS or ICS+LABAs
Number of subjects: 1681
Study: 20031619

Group type: EXPERIMENTAL
Intervention: Genetic testing for sarcomere mutations in MYBPC3, MYH7, and TNNT2.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genetic testing for sarcomere mutations in MYH7.
Number of subjects: 3
Study: 20031626

Group type: EXPERIMENTAL
Intervention: Genetic variants in the 4q25 chromosomal region (specifically SNPs rs2200733, rs13143308, and 5 other linked SNPs)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: SNPs rs2200733 and rs13143308
Number of subjects: 1453
Study: 20031772

Group type: EXPERIMENTAL
Intervention: Diabetes duration >=10 years
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diabetes duration <10 years
Number of subjects: 54
Study: 20032009

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed to smokers (60%)
Number of subjects: 2549

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed to smokers
Number of subjects: 2549
Study: 20032495

Group type: EXPERIMENTAL
Intervention: SNP rs266729 in ADIPOQ
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: SNP rs10920533 in ADIPOR1
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Reduction in plasma saturated fatty acids (SFAs)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Personalized dietary advice to decrease SFA consumption
Number of subjects: 451
Study: 20034959

Group type: EXPERIMENTAL
Intervention: Hellenic-SCORE
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology Systematic Coronary Risk Estimation
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Framingham equations
Number of subjects: 1501
Study: 20035583

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20-70 mg/day
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 318
Study: 20036194

Group type: EXPERIMENTAL
Intervention: Figitumumab (20 mg/kg)
Number of subjects: 29
Study: 20038731

Group type: EXPERIMENTAL
Intervention: SNP rs16754 (WT1(AG/GG))
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: NPM1/FLT3-ITD high-risk patients with SNP rs16754
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with at least one minor allele of SNP rs16754
Number of subjects: 249

Group type: COMPARATOR
Intervention: Patients with or without acquired WT1 mutations
Number of subjects: 249
Study: 20038754

Group type: EXPERIMENTAL
Intervention: Relative plasma volume (RPV) monitoring using the Crit-Line monitor at baseline and at 8 weeks in the intervention group of 100 patients.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Relative plasma volume (RPV) monitoring using the Crit-Line monitor at baseline and at 8 weeks in the control group of 50 patients.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Probing dry weight in patients with flat RPV slopes.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Baseline RPV slopes and change in RPV slopes.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with the flattest RPV slopes.
Number of subjects: 150
Study: 20039102

Group type: EXPERIMENTAL
Intervention: Platelet aggregation in response to adenosine-5'-diphosphate (ADP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Platelet aggregation in response to epinephrine (EPI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Platelet aggregation in response to arachidonic acid (AA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Platelet aggregation in response to collagen (COL)
Number of subjects: 36
Study: 20039404

Group type: EXPERIMENTAL
Intervention: Belimumab plus standard of care therapy
Number of subjects: 17
Study: 20040671

Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20041945

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (200-800 mg/day) infused over 10, 15, and 30 min for 2-5 days
Number of subjects: 160
Study: 20042642

Group type: COMPARATOR
Intervention: Glycerol solution (0.57 g/mL) ingested at 3 mL/kg body weight (maximum, 250 mL)
Number of subjects: 18
Study: 20042848

Group type: EXPERIMENTAL
Intervention: Circumcision of male partner
Number of subjects: 1096
Study: 20045568

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 256

Group type: COMPARATOR
Intervention: No Simvastatin (Control)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: History of disc hemorrhage
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: History of cerebrovascular accidents
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Baseline age
Number of subjects: 256
Study: 20045791

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg subcutaneous dose on day 9)
Number of subjects: 58
Study: 20046132

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bedside cycle ergometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom-designed technological aids for ambulating mechanically ventilated patients
Number of subjects: 0
Study: 20048179

Group type: EXPERIMENTAL
Intervention: HAI of FUDR (0.2 mg/m²/d) and dexamethasone, alternating with systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Systemic therapy of oxaliplatin (130 mg/m²) and capecitabine (1,000 mg/m² twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: HAI of FUDR and systemic therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Protocol-directed therapy
Number of subjects: 76
Study: 20048218

Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the serotonin(2A)-specific radioligand fluorine 18-labeled altanserin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuropsychological test battery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30
Study: 20051022

Group type: EXPERIMENTAL
Intervention: 1-year outpatient intervention based on exercise, behavior, and nutrition therapy
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Former SGA status
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 341
Study: 20051130

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of CBT and SRT (COMB)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 488
Study: 20052480

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 microg/mm(2))
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon only
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 118
Study: 20053869

Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, thalidomide, and defibrotide
Number of subjects: 24
Study: 20055930

Group type: EXPERIMENTAL
Intervention: Individual peer counselling for exclusive breastfeeding
Number of subjects: 12
Study: 20055999

Group type: EXPERIMENTAL
Intervention: Infrared (IR) imaging of the breast
Number of subjects: 276
Study: 20056794

Group type: EXPERIMENTAL
Intervention: KIT mutations
Number of subjects: 203

Group type: COMPARATOR
Intervention: Wild-type KIT
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Location of the KIT mutation and analysis by cytogenetic subtype [t(8;21) vs inv(16)]
Number of subjects: 203
Study: 20057899

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) with respiratory disturbance index >37/hour
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) with mean SaO(2) below 93.5%
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 130
Study: 20060484

Group type: EXPERIMENTAL
Intervention: Lamivudine prophylaxis in high-risk patients (11 of 25 anti-HBc positive, 2 of 2 HBsAg positive, 3 of 3 from HBsAg positive donors)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No prophylaxis in untreated high-risk patients
Number of subjects: 117

Group type: COMPARATOR
Intervention: Low-risk patients (87 recipients negative for HBsAg, anti-HBc, and HBV-DNA)
Number of subjects: 117
Study: 20061136

Group type: EXPERIMENTAL
Intervention: Cediranib 30mg/day with gefitinib 250mg/day (part A1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cediranib 45mg/day with gefitinib 500mg/day (part B1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination treatment (cediranib and gefitinib)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of cediranib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of gefitinib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic assessments
Number of subjects: 90
Study: 20064072

Group type: EXPERIMENTAL
Intervention: 30 mg vicriviroc
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 20 mg vicriviroc
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 20064208

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIT) performed three times weekly by Group A participants.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity performed three times weekly by Group B participants.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (secondary 5 participants).
Number of subjects: 100
Study: 20065126

Group type: EXPERIMENTAL
Intervention: Pramipexole with levodopa infusion
Number of subjects: 13
Study: 20065211

Group type: COMPARATOR
Intervention: Single-vision lenses (n = 41)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: +1.50-D executive bifocals (n = 48)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: +1.50-D executive bifocals with a 3-prism diopters base-in prism (n = 46)
Number of subjects: 135
Study: 20065212

Group type: EXPERIMENTAL
Intervention: Intraocular lenses (IOLs) with spectacles for residual refractive error correction
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lenses
Number of subjects: 114
Study: 20065219

Group type: EXPERIMENTAL
Intervention: 6-month endothelial cell density (ECD) of less than 1700 cells/mm²
Number of subjects: 500

Group type: COMPARATOR
Intervention: 6-month endothelial cell density (ECD) of 2500 cells/mm² or higher
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Preoperative ECD
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 6-month ECD
Number of subjects: 500
Study: 20065758

Group type: EXPERIMENTAL
Intervention: Visceral adiposity (140 patients)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Subcutaneous adiposity (141 patients)
Number of subjects: 281
Study: 20067838

Group type: EXPERIMENTAL
Intervention: Plerixafor (single agent, subcutaneous)
Number of subjects: 9
Study: 20070835

Group type: EXPERIMENTAL
Intervention: Organic sunscreen
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Activities (not specified as a separate group)
Number of subjects: 22
Study: 20071660

Group type: EXPERIMENTAL
Intervention: Infusions of donor-derived, ex vivo-expanded CD8(+) cytotoxic T lymphocyte (CTL) clones specific for tissue-restricted recipient mHAgs
Number of subjects: 7
Study: 20074827

Group type: EXPERIMENTAL
Intervention: Automated mathematical algorithm for EEG analysis during hypoglycemia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Number of subjects: 15
Study: 20075384

Group type: EXPERIMENTAL
Intervention: Higher vitamin D levels
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vitamin D insufficiency (<30 ng/ml)
Number of subjects: 54
Study: 20078436

Group type: EXPERIMENTAL
Intervention: h-FABP (immunodetection with CardioDetect)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: IMA (albumin cobalt-binding test)
Number of subjects: 677

Group type: COMPARATOR
Intervention: h-FABP and IMA combined with usual diagnostic tools
Number of subjects: 677
Study: 20078876

Group type: EXPERIMENTAL
Intervention: Challenge dose of monovalent HBV vaccine
Number of subjects: 301
Study: 20080236

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4mg once daily
Number of subjects: 1353
Study: 20081096

Group type: EXPERIMENTAL
Intervention: Electronic nose
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fractional exhaled nitric oxide (FENO)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lung function testing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of electronic nose and FENO
Number of subjects: 51
Study: 20082451

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 2504
Study: 20082929

Group type: EXPERIMENTAL
Intervention: JUPITER-eligible individuals (hs-CRP > or = 2.0 mg/l, LDL-C <130 mg/dl)
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Placebo group from the JUPITER study
Number of subjects: 1621
Study: 20087581

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with platinum/taxane-based regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Foxp3(+) cell density post-NAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High granzyme B(+)/Foxp3(+) ratio post-NAC
Number of subjects: 0
Study: 20088934

Group type: EXPERIMENTAL
Intervention: Dalteparin at a prophylactic dose
Number of subjects: 0
Study: 20089469

Group type: EXPERIMENTAL
Intervention: Lingualized occlusion (LO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fully bilateral balanced articulation (FBBA)
Number of subjects: 22
Study: 20090835

Group type: EXPERIMENTAL
Intervention: Friedreich's ataxia patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20090916

Group type: EXPERIMENTAL
Intervention: Therapeutic hepatitis B DNA vaccination
Number of subjects: 0
Study: 20092642

Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccination
Number of subjects: 10
Study: 20093349

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg orally, twice daily plus intravenous methylprednisolone (1 to 3 g) followed by oral prednisone (1 mg/kg per day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (Cyclophosphamide plus corticosteroids)
Number of subjects: 17
Study: 20093898

Group type: EXPERIMENTAL
Intervention: Standard medical abortion care with mifepristone-misoprostol
Number of subjects: 3054

Group type: EXPERIMENTAL
Intervention: Screening algorithms including patient-observed outcomes, a low-sensitivity pregnancy test, and nonsonographic clinical evaluation
Number of subjects: 3054
Study: 20095074

Group type: EXPERIMENTAL
Intervention: HAART initiated at CD4 cell counts 351-450 cells/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4 cell counts less than 200 cells/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4 cell counts 400-600 cells/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4 cell counts greater than 600 cells/ml
Number of subjects: 0
Study: 20096224

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 302
Study: 20096225

Group type: EXPERIMENTAL
Intervention: Patients with eosinophilia
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patients without eosinophilia or polyps
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patients with eosinophilia but without polyps
Number of subjects: 102
Study: 20096659

Group type: EXPERIMENTAL
Intervention: Electronic feedback system (EFS)
Number of subjects: 160
Study: 20098520

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 20098527

Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to standard antidepressant therapy (ADT)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study: 20098640

Group type: EXPERIMENTAL
Intervention: self-help booklet with telephone support from a vestibular therapist
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: self-help booklet alone
Number of subjects: 330

Group type: COMPARATOR
Intervention: routine medical care
Number of subjects: 330
Study: 20098694

Group type: EXPERIMENTAL
Intervention: Ixabepilone (BMS-247550) at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ixabepilone (BMS-247550)
Number of subjects: 24
Study: 20100797

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: BASDAI clinical response
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: ASQOL quality of life response
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Absenteeism
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: WPAI:SpA
Number of subjects: 315
Study: 20101385

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow blood autotransplantation
Number of subjects: 0
Study: 20101893

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (initiated at baseline, evaluated at 2 weeks and 6 weeks)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Baseline measurements (before treatment)
Number of subjects: 1
Study: 20102271

Group type: EXPERIMENTAL
Intervention: Presence of minority Y181C mutants in adherent patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Presence of minority Y181C mutants in nonadherent patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Minority Y181C variants
Number of subjects: 195
Study: 20102281

Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a/ribavirin
Number of subjects: 70
Study: 20102307

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Inhaled bronchodilators)
Number of subjects: 0
Study: 20102607

Group type: EXPERIMENTAL
Intervention: Implementation of the NVOG guideline and MOET-instructions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Tailored strategy to implement the NVOG guideline and MOET-instructions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with 30 professionals and 10 patients
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Questionnaire study among all Dutch gynaecologists and midwives
Number of subjects: 320
Study: 20106720

Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks) followed by chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily) and total mesorectal excision.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 105
Study: 20107214

Group type: EXPERIMENTAL
Intervention: Two doses of live, oral rotavirus vaccine
Number of subjects: 4939

Group type: EXPERIMENTAL
Intervention: Three doses of live, oral rotavirus vaccine
Number of subjects: 4939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4939

Group type: EXPERIMENTAL
Intervention: Pooled vaccine group (two or three doses of vaccine)
Number of subjects: 4939

Group type: EXPERIMENTAL
Intervention: Pooled vaccine group
Number of subjects: 4939
Study: 20107229

Group type: EXPERIMENTAL
Intervention: CD8(+) T cells capable of secreting interferon-gamma (IFN-gamma) detected at 8 weeks after transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery of CD4(+)CD45RA(+) T cells and reconstitution of thymopoiesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mug DNA
Number of subjects: 0
Study: 20109568

Group type: EXPERIMENTAL
Intervention: MSCs from third party unrelated donors
Number of subjects: 20

Group type: COMPARATOR
Intervention: HLA-mismatched PBSCs without MSCs (historic control)
Number of subjects: 20
Study: 20110053

Group type: EXPERIMENTAL
Intervention: Nilotinib 200 mg (single oral dose)
Number of subjects: 27
Study: 20111582

Group type: EXPERIMENTAL
Intervention: ADVAX (0.2 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ADVAX (1.0 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ADVAX (4.0 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ADVAX
Number of subjects: 45
Study: 20112079

Group type: EXPERIMENTAL
Intervention: Oral gabapentin 600 mg administered 90 min prior to induction of anesthesia, then every eight hours for a total of four doses
Number of subjects: 16
Study: 20112381

Group type: EXPERIMENTAL
Intervention: Tocilizumab 2 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tocilizumab (all dosages)
Number of subjects: 16